# US 2025/0027107 A1 · Dna compositions and related methods

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0027107 A1
- Document ID: US20250027107A1
- Status: Published application
- Kind: A1
- Application number: 18/702,197
- Filed: 2022-10-18
- Published: 2025-01-23
- Earliest claimed: 2021-10-18
- Assignees: Flagship Pioneering Innovations Vii, LLC
- Applicants: Flagship Pioneering Innovations Vii, LLC
- Inventors: Alexandra Rachael Sneider; Jacob Rosenblum Rubens; Narahari Subbanna Pujar; Molly Krisann Gibson; Benjamin Andrew Portney; Geoffrey A. von Maltzahn; Camilo Ayala Breton
- Web page: https://patentgrep.com/patent/US20250027107A1

## CPC

- A61K 31/7115: Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
- C12N 15/10: Processes for the isolation, preparation or purification of DNA or RNA (chemical preparation of DNA or RNA C07H21/00; preparation of non-structural polynucleotides from microorganisms or with enzymes C12P19/34)
- A61K 9/127: Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K 9/5123: {Organic compounds, e.g. fats, sugars}
- A61K 38/215: {IFN-beta}
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K 48/0033: {the non-active part being non-polymeric}
- A61K 48/0066: {Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid}
- C12N 15/11: DNA or RNA fragments; Modified forms thereof (DNA or RNA not used in recombinant technology, C07H21/00); {Non-coding nucleic acids having a biological activity}
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 15/66: General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
- C12N 15/85: for animal cells
- C12P 19/34: Polynucleotides, e.g. nucleic acids, oligoribonucleotides
- C12Y 301/00: Hydrolases acting on ester bonds (3.1)
- C12Y 301/11002: Exodeoxyribonuclease III (3.1.11.2)
- C12Y 605/01001: DNA ligase (ATP) (6.5.1.1)
- C12N 2310/141: MicroRNAs, miRNAs
- C12N 2310/532: Closed or circular
- C12N 2320/30: Special therapeutic applications
- C12N 2830/00: Vector systems having a special element relevant for transcription
- C12N 2830/46: elements influencing chromatin structure, e.g. scaffold/matrix attachment region, methylation free island
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12P: FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE {(brewing of beer C12C; producing vinegar C12J; producing specific peptides or proteins C07K; producing enzymes C12N9/00; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; measuring or testing processes involving enzymes or microorganisms C12Q; measuring or testing processes involving nucleic acid amplification reactions C12Q1/6844; fermentation processes to form a food composition, A21 or A23; compounds in general, see the relevant compound class, e.g. C01, C07)}
- C12Y: ENZYMES

## Abstract

The disclosure provides, for example, single stranded, covalently closed DNA that does not form a double stranded structure longer than 100 base pairs. The ssDNA may encode an effector sequence, for instance a therapeutic protein. The ssDNA may comprise a nuclear targeting sequence (NTS). In some embodiments, the ssDNA shows decreased activation of the innate immune system compared to an otherwise similar dsDNA.

## Claims

### Claim at position 1

-85. (canceled)

### Claim 86

A method of making a circular, single stranded DNA (ssDNA), the method comprising:
a) providing a circular dsDNA;
b) introducing a discontinuity into one strand of the circular dsDNA, thereby producing a dsDNA having a discontinuity; and
c) contacting the dsDNA having the discontinuity with an exonuclease under conditions that allow for degradation of the nicked strand,
wherein one or both of:
I) the circular dsDNA:
i) lacks a plasmid backbone;
ii) lacks a bacterial origin of replication;
iii) lacks a selectable marker; or
iv) comprises a chemical modification; or
II) the nicking endonuclease is chosen from Nb.BsrDI or Nt.BspQI;
thereby making the circular, ssDNA.

### Claim 87

A composition comprising:
a covalently closed, single stranded DNA (ssDNA) comprising an effector sequence,
wherein one or more of:
a) at least 70%, 80%, 85%, 90%, 95%, 96%, 97%, or 98%, or 99% by mass of total DNA in the composition is the covalently closed ssDNA;
b) at least 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% by mass of total DNA in the composition is full length;
c) less than 10%, 5%, 4%, 3%, 2%, or 1% by mass of DNA in the composition is double stranded DNA (dsDNA);
d) less than 10%, 5%, 4%, 3%, 2%, or 1% by mass of DNA in the composition is linear DNA;
e) less than 10%, 5%, 4%, 3%, 2%, or 1% by mass of DNA in the composition is linear SSDNA;
f) the composition is substantially free of chloroform;
g) the composition is substantially free of phenol;
h) the composition is substantially free of phenol and chloroform;
i) the composition is substantially free of organic solvents;
j) the composition is substantially free of aromatic organic solvents;
k) the ssDNA was produced by a method that does not comprise a phenol-chloroform extraction step;
l) the composition is substantially free of Exonuclease III;
m) the composition is substantially free of T7 Exonuclease;
n) the composition is substantially free of T5 Exonuclease; or
o) the composition comprises at least 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 mg of the covalently closed ssDNA.

### Claim 88

A composition comprising:
a circular double stranded DNA comprising an effector sequence and comprising at least one modified nucleotide, and
Nb.BsrDI or Nt.BspQI.

### Claim 89 (depends on 87)

The composition of claim 87, wherein the ssDNA is not disposed in a carrier.

### Claim 90 (depends on 87)

The composition of claim 87, further comprising a carrier.

### Claim 91 (depends on 90)

The composition of claim 90, wherein the carrier is a lipid nanoparticle (LNP).

### Claim 92 (depends on 87)

The composition of claim 87, formulated for naked administration, parenteral administration, or topical administration.

### Claim 93 (depends on 87)

The composition of claim 87, being substantially free of impurities or byproducts selected from the group consisting of: endotoxin, mononucleotides, modified mononucleotides, double stranded DNA, DNA fragments or truncations, and proteins.

### Claim 94

A method of evaluating a sample of a composition comprising ssDNA, the method comprising determining whether a condition is satisfied, wherein the condition is chosen from:
a) at least 70%, 80%, 85%, 90%, 95%, 97%, or 98%, or 99% by mass of total DNA in the composition is the covalently closed ssDNA;
b) at least 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% by mass of total DNA in the composition is full length;
c) less than 10%, 5%, 4%, 3%, 2%, or 1% by mass of DNA in the composition is double stranded DNA (dsDNA);
d) less than 10%, 5%, 4%, 3%, 2%, or 1% by mass of DNA in the composition is linear DNA;
e) less than 10%, 5%, 4%, 3%, 2%, or 1% by mass of DNA in the composition is linear SSDNA;
f) the composition is substantially free of chloroform;
g) the composition is substantially free of phenol;
h) the composition is substantially free of phenol and chloroform;
i) the composition is substantially free of organic solvents;
j) the composition is substantially free of aromatic organic solvents;
k) the composition is substantially free of Exonuclease III;
l) the composition is substantially free of T7 Exonuclease; or
m) the composition is substantially free of T5 Exonuclease.

### Claim 95 (depends on 87)

A method of delivering an effector to a subject, comprising administering to the subject the composition of claim 87.

### Claim 96 (depends on 87)

A method of modulating a biological parameter in a cell, tissue or subject, comprising administering to the cell, tissue or subject the composition of claim 87.

### Claim 97 (depends on 87)

A method of treating a cell, tissue or subject, comprising administering to the cell, tissue or subject the composition of claim 87.

### Claim 98 (depends on 87)

The composition of claim 87, wherein the ssDNA does not form a double stranded structure longer than 100 base pairs.

### Claim 99 (depends on 87)

The composition of claim 87, wherein the ssDNA comprises a chemical modification.

### Claim 100 (depends on 87)

The composition of claim 87, wherein:
a) the ssDNA is not a bacteriophage genome;
b) the ssDNA lacks a bacteriophage packaging site;
c) the ssDNA lacks a bacteriophage origin of replication;
d) the ssDNA does not encode a bacteriophage capsid gene;
e) the ssDNA was not produced by rolling circle amplification;
f) the ssDNA was not produced by strand displacement amplification;
g) the ssDNA does not comprise a protelomerase target sequence;
h) the ssDNA does not comprise a hairpin structure;
i) the ssDNA does not comprise a first sequence that hybridizes with a second sequence, wherein the first sequence and the second sequence are at least 5 nt long, and wherein the first sequence and the second sequence are positioned less than 6 nucleotides apart from each other;
j) the ssDNA does not comprise a double strand origin (DSO);
k) the ssDNA further comprises a nuclear targeting sequence (NTS);
l) the ssDNA further comprises a maintenance sequence;
m) the ssDNA further comprises a second strand motif (SSM);
n) the ssDNA comprises between 20-20,000 nucleotides;
o) the ssDNA is a sense ssDNA strand; or
p) the ssDNA is an antisense ssDNA strand.

### Claim 101 (depends on 87)

The composition of claim 87, wherein the effector sequence is a therapeutically functional sequence that is a DNA sequence comprising a DNA aptamer, DNAzyme or allele-specific oligonucleotide (ASO).

### Claim 102 (depends on 87)

The composition of claim 87, wherein the effector sequence is a therapeutically functional sequence that comprises a promoter sequence operably linked to a sequence encoding a therapeutic RNA or polypeptide.

### Claim 103 (depends on 102)

The composition of claim 102, wherein the promoter sequence is operably linked to a sequence encoding a therapeutic RNA selected from the group consisting of: tRNA, lncRNA, miRNA, rRNA, snRNA, microRNA, siRNA, piRNA, snoRNA, snRNA, exRNA, scaRNA, Y RNA, and hnRNA.

### Claim 104 (depends on 102)

The composition of claim 102, wherein the promoter sequence is operably linked to a sequence encoding a therapeutic polypeptide selected from the group consisting of: a transcription factor, a chromatin remodeling factor, an antigen, a hormone, an enzyme, a Crispr-linked enzyme, a mobile genetic element protein, a gene writer, a polymerase, a methylase, a demethylase, an acetylase, a deacetylase, a kinase, a phosphatase, a ligase, a deubiquitinase, an integrase, a recombinase, a topoisomerase, a gyrase, a helicase, a lysosomal acid hydrolase, an antibody, a receptor ligand, a receptor, a clotting factor, a membrane protein, a mitochondrial protein, a nuclear protein, a centyrin, a darpin, and an adnectin.

### Claim 105 (depends on 87)

The composition of claim 87, wherein the ssDNA comprises a second effector sequence which is the same as or different from the first effector sequence.

### Claim 106

A pharmaceutical formulation comprising:
an LNP comprising a single stranded DNA (ssDNA), wherein the ssDNA:
(a) encodes a therapeutic protein,
(b) is covalently closed,
(c) does not form a double stranded structure longer than 100 base pairs,
(d) is more than 200 nucleotides in length, and
(e) does not comprise a protelomerase target sequence; and
wherein the pharmaceutical formulation is substantially free of linear DNA and protein.

### Claim 107 (depends on 106)

A method of delivering a therapeutic protein to a subject, comprising administering to the subject the pharmaceutical formulation of claim 106.

### Claim 108 (depends on 106)

A method of modulating a biological parameter in a cell, tissue or subject, comprising administering to the cell, tissue or subject the pharmaceutical formulation of claim 106.

### Claim 109 (depends on 106)

A method of treating a cell, tissue or subject, comprising administering to the cell, tissue or subject the pharmaceutical formulation of claim 106.

### Claim 110

A pharmaceutical formulation comprising:
an LNP comprising a single stranded DNA (ssDNA), wherein the ssDNA:
(a) comprises an effector sequence,
(b) is covalently closed,
(c) does not form a double stranded structure longer than 40 base pairs,
(d) is more than 200 nucleotides in length, and
(e) does not comprise a protelomerase target sequence.

### Claim 111 (depends on 110)

A method of delivering a therapeutic protein to a subject, comprising administering to the subject the pharmaceutical formulation of claim 110.

### Claim 112 (depends on 110)

A method of modulating a biological parameter in a cell, tissue or subject, comprising administering to the cell, tissue or subject the pharmaceutical formulation of claim 110.

### Claim 113 (depends on 110)

A method of treating a cell, tissue or subject, comprising administering to the cell, tissue or subject the pharmaceutical formulation of claim 110.
